Ascentage Pharma Group International (AAPG) Invested Capital (2022 - 2025)

Ascentage Pharma Group International (AAPG) has disclosed Invested Capital for 4 consecutive years, with $188.2 million as the latest value for Q4 2025.

  • For Q4 2025, Invested Capital rose 409.25% year-over-year to $188.2 million; the TTM value through Dec 2025 reached $188.2 million, up 409.25%, while the annual FY2025 figure was $185.7 million, 4353.23% up from the prior year.
  • Invested Capital hit $188.2 million in Q4 2025 for Ascentage Pharma Group International, up from $37.0 million in the prior quarter.
  • Across five years, Invested Capital topped out at $188.2 million in Q4 2025 and bottomed at $13.0 million in Q4 2023.
  • Average Invested Capital over 4 years is $73.9 million, with a median of $47.2 million recorded in 2022.
  • Year-over-year, Invested Capital plummeted 77.47% in 2023 and then surged 409.25% in 2025.
  • Ascentage Pharma Group International's Invested Capital stood at $57.5 million in 2022, then tumbled by 77.47% to $13.0 million in 2023, then surged by 185.15% to $37.0 million in 2024, then soared by 409.25% to $188.2 million in 2025.
  • According to Business Quant data, Invested Capital over the past three periods came in at $188.2 million, $37.0 million, and $13.0 million for Q4 2025, Q4 2024, and Q4 2023 respectively.